Gilead Sciences Inc. (NYSE: GILD) was ordered to pay about $1.8 million late last week in attorney’s fees and legal expenses to shareholders who sued the company after they were...
Leerink Partners analyst Geoff Porges maintained a Buy rating on Gilead Sciences (NASDAQ:GILD) on Monday, setting a price target of $74, which is approximately 7.79% above the...
Gilead Sciences (GILD) has agreed to sell Kite’s Neoantigen TCR Cell Therapy R&D platform and manufacturing plant to BioNTech (BNTX).Kite is a Gilead subsidiary focused on cell...
The healthcare sector has been benefiting from COVID-19 vaccines or treatment with many more to come. The ultra-popular ETFs, Health Care Select Sector SPDR Fund XLV, Vanguard...
After its more than 450% surge during 2020, the meteoric rally in Moderna (NASDAQ:MRNA) shares continues this year. The gains—propelled by the biotech's breakthrough vaccine...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Neutral | Buy | Strong Buy | Strong Buy | Buy |
| Technical Indicators | Strong Sell | Strong Buy | Strong Buy | Strong Buy | Buy |
| Summary | Sell | Strong Buy | Strong Buy | Strong Buy | Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 2,745.40 | 2,765.00 | 2,706.70 | +107.4 | +4.07% | 2.06M | NASDAQ | |||
| 372.59 | 377.54 | 367.00 | +4.78 | +1.30% | 9.58M | NASDAQ | |||
| 195.95 | 196.40 | 189.76 | +9.88 | +5.31% | 17.65M | NYSE | |||
| 43.29 | 43.30 | 42.26 | +1.19 | +2.83% | 19.21M | NYSE | |||
| 53.26 | 53.92 | 52.94 | +0.08 | +0.15% | 11.84M | NASDAQ | |||
| 15.52 | 16.18 | 14.02 | +2.79 | +21.92% | 69.64M | NASDAQ | |||
| 194.50 | 195.25 | 189.95 | +2.42 | +1.26% | 8.26M | NASDAQ | |||
| 41.70 | 41.87 | 39.80 | +2.35 | +5.96% | 34.71M | NYSE | |||
| 20.42 | 20.65 | 20.16 | +0.06 | +0.29% | 2.47M | NYSE | |||
| 240.00 | 242.79 | 238.40 | +4.92 | +2.09% | 1.03M | NASDAQ | |||
| 13.11 | 13.14 | 12.91 | +0.16 | +1.24% | 793.09K | NYSE | |||
| 115.02 | 115.15 | 113.90 | +1.48 | +1.30% | 2.45M | NYSE | |||
| 4.44 | 4.47 | 4.44 | 0.000 | 0.00% | 0.00 | NYSE | |||
| 6.34 | 6.66 | 5.90 | +0.83 | +15.06% | 83.61M | NYSE | |||
| 171.47 | 177.12 | 164.38 | -7.07 | -3.96% | 2.19M | NYSE |
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
